Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
FDA moves to rehire medical device staffers fired only days earlier
The reversal is the latest example of President Donald Trump and billionaire Elon Musk’s chaotic approach to cost-cutting, ...
Drug compounders sue FDA over semaglutide status: report
Makers of copycat versions of Novo Nordisk's (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, ...
manilatimes5m
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.
Why have AIM's multiple mRNA vaccines been able to push for FDA approval in such a short time? First, innovation is in AIM's DNA. The mRNA shingles vaccine, currently submitted for U.S. clinical ...
Adderall shortage continues to impact millions of Americans living with ADHD
ADHD Advisor examined data from the Drug Enforcement Administration and other sources to see why the Adderall shortage ...
dvm36055m
New guide designed to assist veterinary practices with canine OA protocols
American Regent Animal Health created the new resources in collaboration with the UC-Davis professor Denis Marcellin-Little, ...
Stocks to Watch: Hims & Hers Health, Chegg, Wah Fu Education Group
Hims & Hers Health beat fourth-quarter estimates and guided for better-than-expected revenue in the first quarter and 2025. The telehealth provider logged earnings of 11 cents a share on revenue of ...
These 3 healthcare stories are spooking investors. But they shouldn't worry.
Healthcare investors spooked by recent headlines on cuts to Medicare Advantage and a new Justice Department probe of UnitedHealth Group Inc.'s billing practices are worrying about the wrong thing.